News | April 12, 2013

CardioLogical Receives Patent for Aortic Embolic Protection Devices to Prevent During TAVR

Technologies address the three biggest clinical needs to make transcatheter aortic valve replacement (TAVR) safer

Heart with Aorta

April 12, 2013 — CardioLogical Solutions, formed by the recent merger of Emboline and VasoStitch, has been issued an additional patent for its family of aortic embolic protection devices that are designed to prevent stroke and other ischemic complications.

The aortic embolic protection technologies of Emboline and the large-hole access and closure technologies of VasoStitch form the initial core of a suite of accessory devices offered by CardioLogical Solutions to address the clinical needs of emerging interventional cardiology procedures. Added to these is a novel approach to preventing contrast nephropathy during cardiovascular procedures.

“Our three platforms of procedural accessory devices address the three most pressing clinical needs in the rapidly growing evolution of transcatheter aortic valve replacement (TAVR) therapies: specifically, (1) a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy,” said David W. J. Smith, CEO.

CardioLogical Solutions is currently in the advanced stages of raising a Series B preferred round to achieve CE mark for the initial Emboline and VasoStitch products and proof-of-concept for its contrast nephropathy technology.

Related Content

Philips, Azurion platform, angiography, interventional lab, global launch
Technology | Angiography| March 03, 2017
Philips recently announced the global launch of Azurion, its next-generation image-guided therapy platform.
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Mitralign, Trialign System, tricuspid regurgitation, first transcatheter repair, cardiac implantable device lead, Piedmont
News | Heart Valve Technology| November 18, 2016
Mitralign Inc. announced the successful compassionate use treatment of a patient suffering from tricuspid regurgitation...
Videos | Heart Valve Technology| November 18, 2016
A discussion with Juan Granada, M.D., about transcatheter mitral valve advancements and device challenges at the Tran
Videos | Heart Valve Technology| November 18, 2016
A discussion with Torsten Vahl, M.D., about advancements in transcatheter valve repair technology, including new devi
Barco, Nexxis OR imaging management platform, 1,000 installations worldwide, RSNA 2016
News | Flat Panel Displays| November 11, 2016
Barco recently announced that Nexxis, its IP-based OR imaging management platform, is now operating in over 1,000...
NeoChord, RECHORD Trial, first patient, DS1000 System, degenerative mitral regurgitation, DMR
News | Heart Valve Technology| November 10, 2016
NeoChord Inc. announced the first use of its DS1000 System in the United States as it enrolled the first patient in the...
Videos | Structural Heart| November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
Toshiba, Infinix, 4DCT, CT-Angio

Toshiba’s Infinix 4DCT combines an Infinix Elite angiography system an Aquilion One Vision edition CT system. It allows clinicians to plan, treat and verify in a single clinical setting. The CT system is capable of capturing an entire organ in one rotation with 640 slices and 16 cm of anatomical coverage. 

Feature | Angiography| July 12, 2016 | Dave Fornell
Angiographic imaging system vendors have developed new technologies to address emerging cath lab trends, including th
Videos | Cardiovascular Ultrasound| June 28, 2016
Interview with Rebecca Hahn, M.D., FASE, Columbia University Medical Center, New York, at the American Society of Ech
Overlay Init